FGF23 and X-linked hypophosphatemia: As a result, further studies in mice and in patients with XLH showed that a titrated FGF23 blockade significantly increases serum Pi to levels outmatching those achieved by conventional Pi and vitamin D supplementation therapies, with substantial benefits to the skeleton (8, 10).